SCHEMBL25801863

SCHEMBL25801863

CCOP(C)(=O)C(CC(N)=S)C(=O)OC(C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25801865 0.88 NOS1 (0.30)
SCHEMBL23578214 0.87 GAA (0.34)
SCHEMBL25801535 0.84 TSHR (0.31) TSHRSMN1; SMN2
SCHEMBL25801531 0.82 TSHR (0.31) TSHRSMN1; SMN2
SCHEMBL25802002 0.78 MMP8 (0.33)
SCHEMBL23578550 0.75 GAA (0.35) SMN1; SMN2
SCHEMBL25801860 0.72 GAA (0.36)
SCHEMBL5575508 0.70 CYP3A4 (0.38) TSHRSMN1; SMN2
SCHEMBL6819825 0.70 GAA (0.36) TSHRSMN1; SMN2
SCHEMBL25801646 0.69 ALDH1A1 (0.41) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 TSHR 3550/4885SMN1; SMN2 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.